Sugi Predict

Sugi Predict / Targets / FBXL19

FBXL19

F-box/LRR-repeat protein 19 · Q6PCT2 · FBXL19 on Sugi Atlas →

1,891 patent compounds predicted against FBXL19, 805 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL19054826 SCHEMBL19054826 0.44 8/20
SCHEMBL2701157 SCHEMBL2701157 0.69 5/20
SCHEMBL2701160 SCHEMBL2701160 0.69 5/20
Acrylamide Acrylamide (SCHEMBL3714624) 0.42 5/20
Acrylamide Acrylamide (SCHEMBL8498177) 0.42 5/20
SCHEMBL14520965 SCHEMBL14520965 0.72 4/20
SCHEMBL2526026 SCHEMBL2526026 0.64 4/20
SCHEMBL2529201 SCHEMBL2529201 0.57 4/20
SCHEMBL2526312 SCHEMBL2526312 0.55 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2529676) 0.54 4/20
SCHEMBL12216179 SCHEMBL12216179 0.54 4/20
SCHEMBL12018334 SCHEMBL12018334 0.53 4/20
SCHEMBL12195116 SCHEMBL12195116 0.52 4/20
SCHEMBL3790649 SCHEMBL3790649 0.51 4/20
SCHEMBL12987884 SCHEMBL12987884 0.49 4/20
SCHEMBL12987813 SCHEMBL12987813 0.49 4/20
SCHEMBL167151 SCHEMBL167151 0.47 4/20
SCHEMBL12764449 SCHEMBL12764449 0.47 4/20
SCHEMBL12988312 SCHEMBL12988312 0.46 4/20
SCHEMBL3909752 SCHEMBL3909752 0.45 4/20

Clinical trials — most relevant to FBXL19 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Valproate and Levocarnitine in Children With Spinal Muscular Atrophy PHASE3UNKNOWN
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetic Analysis of Fraser Syndrome and Fryns Syndrome nanCOMPLETED
Amyotrophic Lateral Sclerosis (ALS) Families Project nanRECRUITING
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization nanCOMPLETED
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis nanUNKNOWN
Genomic Study of Congenital Malformation nanUNKNOWN
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases nanCOMPLETED
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
18F-FDG PET/TC in TIR3A e TIR3B nanENROLLING_BY_INVITATION
Novel Genetic Disorders of the Immune System nanRECRUITING
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer nanRECRUITING
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
FASHION Fabry Disease Hypertrophic Cardiomyopathy and Infammation nanUNKNOWN
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) nanWITHDRAWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Psychiatric Phenotype Characterization of Individuals With FOXP1 Syndrome nanCOMPLETED
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others nanRECRUITING
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome nanCOMPLETED
Advancing Neurogenetic Diagnoses Through Long-Read Sequencing nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a FBXL19 binder may also engage these)

ProteinNameSimilarity
Q6PB97 — 1.000 Q6PB97 →
Q6PJ61 — 0.985 Q6PJ61 →
Q8BG80 — 0.982 Q8BG80 →
Q5TM48 — 0.982 Q5TM48 →
Q8NCF5 — 0.981 Q8NCF5 →
Q8BLS7 — 0.981 Q8BLS7 →
LMTK3 Serine/threonine-protein kinase LMTK3 0.981 landscape →
Q80XI6 — 0.981 Q80XI6 →
Q5BJT1 — 0.980 Q5BJT1 →
O35615 — 0.980 O35615 →
MAP3K10 Mitogen-activated protein kinase kinase kinase 10 0.980 landscape →
A0A8I3PMN2 — 0.980 A0A8I3PMN2 →
Q2M3V2 — 0.980 Q2M3V2 →
A2AEV7 — 0.980 A2AEV7 →
TESK1 Dual specificity testis-specific protein kinase 1 0.979 landscape →
Q9Y242 — 0.979 Q9Y242 →
O94761 — 0.979 O94761 →
Q66HA1 — 0.979 Q66HA1 →
Q9GLZ9 — 0.979 Q9GLZ9 →
D3ZG83 — 0.979 D3ZG83 →
A8MVW0 — 0.979 A8MVW0 →
Q9TSV4 — 0.979 Q9TSV4 →
Q7YR48 — 0.979 Q7YR48 →
Q8TBE0 — 0.979 Q8TBE0 →
Q6ZVH7 — 0.978 Q6ZVH7 →
Q5RKR3 — 0.978 Q5RKR3 →
A2A699 — 0.978 A2A699 →
Q9UQQ2 — 0.978 Q9UQQ2 →
Q5XJV6 — 0.978 Q5XJV6 →
Q8VDG6 — 0.978 Q8VDG6 →